|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
|
US6617442B1
(en)
|
1999-09-30 |
2003-09-09 |
Isis Pharmaceuticals, Inc. |
Human Rnase H1 and oligonucleotide compositions thereof
|
|
AU2002255478A1
(en)
|
2001-01-10 |
2002-09-12 |
Pe Corporation (Ny) |
Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
|
|
GB0120238D0
(en)
|
2001-08-20 |
2001-10-10 |
Univ College Of London |
Sodium channel regulators and modulators
|
|
ATE556714T1
(de)
|
2002-02-01 |
2012-05-15 |
Life Technologies Corp |
Doppelsträngige oligonukleotide
|
|
US7659082B2
(en)
|
2002-02-19 |
2010-02-09 |
Xenon Pharmaceuticals Inc. |
Methods for identifying analgesic agents
|
|
US20040097440A1
(en)
|
2002-11-11 |
2004-05-20 |
Isis Pharmaceuticals Inc. |
Modulation of jumonji expression
|
|
WO2004016754A2
(en)
*
|
2002-08-14 |
2004-02-26 |
Pharmacia Corporation |
ANTISENSE MODULATION OF Nav1.3 EXPRESSION
|
|
AU2003295600A1
(en)
|
2002-11-14 |
2004-06-15 |
Dharmacon, Inc. |
Functional and hyperfunctional sirna
|
|
US7250496B2
(en)
|
2002-11-14 |
2007-07-31 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory genes and uses thereof
|
|
WO2004046160A2
(en)
|
2002-11-18 |
2004-06-03 |
Santaris Pharma A/S |
Amino-lna, thio-lna and alpha-l-oxy-ln
|
|
US7341835B2
(en)
|
2004-01-13 |
2008-03-11 |
Affymetrix, Inc. |
Methods of analysis of alternative splicing in mouse
|
|
US20050244851A1
(en)
|
2004-01-13 |
2005-11-03 |
Affymetrix, Inc. |
Methods of analysis of alternative splicing in human
|
|
JP5697297B2
(ja)
|
2004-05-14 |
2015-04-08 |
ロゼッタ ジノミクス リミテッド |
マイクロｎａｓおよびその使用
|
|
AR051829A1
(es)
|
2004-10-27 |
2007-02-14 |
Schering Corp |
Composiciones y metodos para inhibicion de nav 1 mediante arn corto de interferencia
|
|
US20070154896A1
(en)
|
2005-02-11 |
2007-07-05 |
International Business Machines Corporation |
System and method for identification of MicroRNA target sites and corresponding targeting MicroRNA sequences
|
|
CA2626584A1
(en)
|
2005-11-04 |
2007-05-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of nav1.8 gene
|
|
US8178503B2
(en)
|
2006-03-03 |
2012-05-15 |
International Business Machines Corporation |
Ribonucleic acid interference molecules and binding sites derived by analyzing intergenic and intronic regions of genomes
|
|
US7901882B2
(en)
|
2006-03-31 |
2011-03-08 |
Affymetrix, Inc. |
Analysis of methylation using nucleic acid arrays
|
|
US20100105134A1
(en)
|
2007-03-02 |
2010-04-29 |
Mdrna, Inc. |
Nucleic acid compounds for inhibiting gene expression and uses thereof
|
|
WO2009033027A2
(en)
|
2007-09-05 |
2009-03-12 |
Medtronic, Inc. |
Suppression of scn9a gene expression and/or function for the treatment of pain
|
|
FR2929292A1
(fr)
|
2008-03-28 |
2009-10-02 |
Exonhit Therapeutics S A Sa |
Procede et methodes de diagnostic de la maladie d'alzheimer
|
|
WO2009143277A2
(en)
*
|
2008-05-20 |
2009-11-26 |
Intradigm Corporation |
Compositions comprising hscn9a sirna and methods of use thereof
|
|
CN109112126B
(zh)
|
2010-06-23 |
2024-06-14 |
库尔纳公司 |
通过抑制电压门控钠通道α亚基(SCNA)的天然反义转录物而治疗SCNA相关疾病
|
|
LT2841578T
(lt)
|
2012-04-23 |
2017-09-25 |
Biomarin Technologies B.V. |
Rnr moduliuojantys oligonukleotidai su pagerintomis savybėmis, skirti neuromuskulinių susirgimų gydymui
|
|
EP2906255B1
(en)
|
2012-10-12 |
2023-02-22 |
Ionis Pharmaceuticals, Inc. |
Antisense compounds and uses thereof
|
|
MX2015010749A
(es)
|
2013-03-14 |
2015-11-30 |
Regeneron Pharma |
Anticuerpos humanos para nav1.7.
|
|
FR3007656B1
(fr)
|
2013-06-28 |
2015-06-26 |
Galderma Res & Dev |
Modulateurs du canal sodique nav1.9 pour le traitement d'une maladie cutanee inflammatoire et methodes diagnostiques
|
|
CA2954791C
(en)
|
2014-07-14 |
2025-11-18 |
The Regents Of The University Of California |
CRISPR/CAS TRANSCRIPTIONAL MODULATION
|
|
CA2958524A1
(en)
|
2014-08-20 |
2016-02-25 |
Lifesplice Pharma Llc |
Splice modulating oligonucleotides and methods of use thereof
|
|
WO2016027168A2
(en)
|
2014-08-20 |
2016-02-25 |
Lifesplice Pharma Llc |
Splice modulating oligonucleotides and methods of use thereof
|
|
MX2017012426A
(es)
|
2015-04-03 |
2018-01-26 |
Ionis Pharmaceuticals Inc |
Composiciones y metodos para modular la expresion de tmprss6.
|
|
WO2017139413A1
(en)
|
2016-02-08 |
2017-08-17 |
Circuit Therapeutics, Inc. |
System and method to modulate pain and itch through cutaneous transfer of genetic information
|
|
KR102189358B1
(ko)
|
2016-06-03 |
2020-12-09 |
주식회사 씨젠 |
올리고뉴클레오타이드의 특이성 평가
|
|
JP7305534B2
(ja)
|
2016-07-06 |
2023-07-10 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
疼痛関連障害を処置するための物質及び方法
|
|
CN109843914B
(zh)
|
2016-07-06 |
2024-03-15 |
沃泰克斯药物股份有限公司 |
用于治疗疼痛相关病症的材料和方法
|
|
US11504391B1
(en)
*
|
2016-11-23 |
2022-11-22 |
Alnylam Pharmaceuticals, Inc. |
Modified RNA agents with reduced off-target effect
|
|
SG11201905601VA
(en)
*
|
2017-01-24 |
2019-08-27 |
Olipass Corp |
Scn9a antisense pain killer
|
|
EP3592853A1
(en)
|
2017-03-09 |
2020-01-15 |
President and Fellows of Harvard College |
Suppression of pain by gene editing
|
|
EP3810776A1
(en)
|
2018-06-22 |
2021-04-28 |
F. Hoffmann-La Roche AG |
Oligonucleotides for modulating scn9a expression
|
|
WO2020191233A1
(en)
|
2019-03-19 |
2020-09-24 |
The Broad Institute, Inc. |
Methods and compositions for editing nucleotide sequences
|
|
JP2023542889A
(ja)
|
2020-09-17 |
2023-10-12 |
キュー－ステート バイオサイエンシーズ， インコーポレイテッド |
複数の標的を介して疼痛を処置するための治療用組成物
|
|
WO2022232395A2
(en)
|
2021-04-28 |
2022-11-03 |
Q-State Biosciences, Inc. |
Therapeutic compositions for treating pain via multiple targets
|